+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P05034(MAGEC1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P05034(MAGEC1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

MAGEC1 (Melanoma-associated antigen C1), also known as MAGE-C1. is a member of the MAGE (melanoma-associated antigen) family of proteins. This family is characterized by shared MAGE homology domains and is primarily implicated in cancer biology. MAGEC1 is classified as a cancer-testis (CT) antigen due to its restricted expression pattern: it is typically absent in most normal adult tissues but is reactivated in various malignancies, including melanoma, multiple myeloma, hepatocellular carcinoma, and lung cancer. This tumor-specific expression makes MAGEC1 a promising target for cancer immunotherapy and biomarker research.

The MAGEC1 gene is located on the X chromosome (Xq26-27) and encodes a protein involved in regulating transcription, apoptosis, and cell cycle progression. Its overexpression in tumors is associated with poor prognosis and resistance to therapy, likely due to its role in promoting oncogenic pathways and immune evasion. MAGEC1 antibodies are critical tools for detecting its expression in cancer cells, enabling studies on its functional mechanisms, diagnostic potential, and therapeutic targeting. These antibodies are used in techniques like immunohistochemistry, Western blotting, and flow cytometry to evaluate MAGEC1 expression patterns in clinical samples or experimental models. Recent research explores MAGEC1-targeted approaches, including vaccines and adoptive T-cell therapies, highlighting its relevance in advancing personalized oncology treatments. However, challenges remain in understanding its precise molecular interactions and optimizing immunogenic responses in therapeutic contexts.